SESIP Paves the Way for IoT Manufacturers to Meet New European Cybersecurity Rules
12.12.2024 09:00:00 CET | Business Wire | Press release
GlobalPlatform’s SESIP methodology (EN 17927) offers a streamlined, cost-effective security framework for connected devices and components to conform to the EU’s new Cyber Resilience Act
GlobalPlatform is calling for manufacturers of connected devices and components to adopt its “Security Evaluation Standard for IoT Platforms” (SESIP) methodology to demonstrate conformance with the European Union’s new Cyber Resilience Act (CRA), which comes into force this month. The CRA aims to strengthen and harmonize cybersecurity across the EU by creating a new legal framework for all products that connect to the internet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211681976/en/

(Graphic: Business Wire)
The enactment of the CRA puts into place mandatory cybersecurity rules that span the entire lifecycle of a digital product sold in the EU. The CRA was published in the Official Journal of the European Union last month and becomes law on December 11, 2024. Product manufacturers will have 36 months to fully comply with the legislation. The Act will eventually require all relevant products to comply with the rules in order to obtain the CE marking, a mandatory market requirement for issuing products in Europe.
As an internationally recognized standard for IoT security evaluation, SESIP is key to meeting the requirements mandated by the CRA. It provides manufacturers with a proven methodology for conducting security evaluations of software and hardware components across their products and supply chains. SESIP is recognized as a standard by CENELEC, the European Standardization Organization, as EN 17927. It also aligns with many other legislation and vertical certification schemes around the world, including the Cyber Trust Mark in the US.
The methodology is being used to certify components, platforms, and modules from a range of companies and is supported by a growing ecosystem of security providers, certification bodies (CBs), security laboratories, and other stakeholders. GlobalPlatform continues to support the growth and governance of the SESIP ecosystem. SGS Brightsight has recently been accredited as a SESIP CB following approval from the Spanish national accreditation body (ENAC), becoming the second SESIP CB after TrustCB.
“Industry support for SESIP is building at this critical juncture for IoT manufacturers operating in Europe,” said Gil Bernabeu, CTO of GlobalPlatform. “The Cyber Resilience Act is vital to protecting consumers and businesses by embedding security features into the heart of the connected devices we use every day, providing a cybersecurity framework that spans the design, development, and maintenance of digital products.
“However, this landmark legislation presents a range of compliance challenges for manufacturers of connected devices and the components used in these products,” continued Bernabeu. “SESIP simplifies conformity with the new regulations by providing a unified framework for comprehensive security evaluation, reducing cost, risk, and time to market. We look forward to expanding the SESIP ecosystem to help multiple industry sectors meet the requirements of the new European regulations. It will also enable international manufacturers to reuse their security evaluation investments to demonstrate conformance to non-European regulations.”
The SESIP methodology is already mapped to other standards and regulations such as ETSI, (EN 303645 / TS 103732), ISO/IEC (62443-4-2), RED (EN 18031), UNECE WP.29 (ISO/SAE 21434) and NIST (NIST 8259 / NIST 8425). It is also being used by schemes such as PSA Certified, and standardization bodies including the Car Connectivity Consortium and the Wireless Power Consortium. In addition to Europe, SESIP is being adopted around the world in key markets such as China, where an agreement was recently reached between GlobalPlatform and China’s National Financial Technology Certification Center (NFTC).
GlobalPlatform has a number of initiatives in place to help accelerate SESIP adoption. A training program has been launched and available for any interested party. It has also launched the SESIP Adopters community to give non-members the ability to keep up to date with relevant technical documents and showcase certified SESIP products.
For more information on SESIP please visit: https://globalplatform.org/sesip/
About GlobalPlatform
GlobalPlatform is a technical standards organization that enables the efficient launch and management of innovative, secure-by-design digital services and devices, which deliver end-to-end security, privacy, simplicity, and convenience to users. It achieves this by providing standardized technologies and certifications that empower technology and service providers to develop, certify, deploy, and manage digital services and devices in line with their business, security, regulatory and data protection needs. GlobalPlatform technologies are used in billions of smart cards, smartphones, wearables and other connected and IoT devices.
GlobalPlatform standardized technologies and certifications are developed through effective industry-driven collaboration, led by multiple diverse member companies working in partnership with industry and regulatory bodies and other interested parties from around the world.
globalplatform.org | Twitter / X | LinkedIn | YouTube | GitHub | WeChat
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211681976/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom